• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eisai Ltd ADR (OP:ESALY)

N/A UNCHANGED
Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eisai Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >
News headline image
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs ↗
June 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
News headline image
Bristol Myers Inks Licensing Pact For Eisai's Folate Receptor ADC Drug, Lays Out Over $3B For Rights ↗
June 18, 2021
Eisai Co Ltd (OTC: ESALY) and Bristol-Myers Squibb Co (NYSE: BMY) have entered into an exclusive global strategic collaboration agreement for the co-... 
Via Benzinga
News headline image
Two Rate Hikes In 2023 ↗
June 16, 2021
This afternoon our Fed chief Jerome Powell predicted there will be interest rate hikes faster than before. The news hit US stocks, gold, and bitcoin hard. 
Via Talk Markets
Topics Economy
News headline image
Continued Uncertainty ↗
June 15, 2021
Fear of another Fukushima yesterday late in the market day led to a rush out of energy-related shares, which included many without any nuclear risk at all. 
Via Talk Markets
News headline image
Dreary Day ↗
June 14, 2021
Another dreary day and a renewed boost for cryptocurrency - and away from the classic inflation hedge, gold. 
Via Talk Markets
News headline image
Happy Friday ↗
June 11, 2021
The inflation risk is being ignored by the US market now that there will probably not be a tax increase and may be higher prices for longer. 
Via Talk Markets
News headline image
Unheeding Markets ↗
June 10, 2021
Today oil prices rose over $70. 
Via Talk Markets
News headline image
Wednesday News And Catch-Up ↗
June 09, 2021
Today the US market resumed its attempt to hit a new record for the S&P 500 and Nasdaq, but not the DJIA. 
Via Talk Markets
Topics Stocks
News headline image
FDA surprise ↗
June 07, 2021
The big news out of China is that its import purchases of copper and iron sagged last month because its export markets are far less strong than earlier this year. 
Via Talk Markets
News headline image
Biogen's Alzheimer's Disease Treatment Earns FDA Approval ↗
June 07, 2021
Aducanumab becomes the first available treatment intended to stop patients with Alzheimer's disease from losing more memories. 
Via The Motley Fool
News headline image
Why Biogen Stock Is On Fire Today ↗
June 07, 2021
The biotech's controversial Alzheimer's disease drug got a green light from the FDA. 
Via The Motley Fool
News headline image
Merck/Eisai's Keytruda-Lenvima Combo Results in Better Health-Related Quality of Life Measures Compared to Sunitinib ↗
June 07, 2021
Merck & Co Inc (NYSE: MRK) has announced new data from Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, which evaluated the combinations of Keytruda (pembrolizumab... 
Via Benzinga
News headline image
A Better Switch ↗
June 04, 2021
Today the US market decided to rise because President Biden is pondering not linking his infrastructure project to a corporate tax increase. 
Via Talk Markets
News headline image
Ahead Of Judgement Day, FDA Faces Test with Biogen's Alzheimer's Drug Decision ↗
June 04, 2021
U.S. regulators are slated to decide by Monday whether to approve Biogen Inc’s (NASDAQ: BIIB) much-talked-about Alzheimer’s disease drug, aducanumab.... 
Via Benzinga
News headline image
Fan Hit ↗
June 03, 2021
The 10-yr US treasury yield rose to 1.6% again. Later in the day, a rally was attempted, mostly for the meme shares. 
Via Talk Markets
News headline image
Wonder Products ↗
June 02, 2021
Meme is alive and well. 
Via Talk Markets
News headline image
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates ↗
June 01, 2021
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive... 
Via Benzinga
News headline image
More Inflationary Pressures ↗
May 28, 2021
Today, we saw more evidence of worrying inflationary pressures from the personal consumption index hitting 3.1% in April over prior April, up sharply from the March rise of 1.9%. 
Via Talk Markets
News headline image
New New Deal Worries ↗
May 27, 2021
Nio is up 1.4% today on another round of Meme buying. 
Via Talk Markets
News headline image
Good Times For Gold ↗
May 26, 2021
Gold is rising some more, in part as an alternative to crypto. 
Via Talk Markets
News headline image
Sterling At Five-Year High ↗
May 25, 2021
Today markets are mixed because of currency factors, with sterling bullishness against the dollar and the euro. 
Via Talk Markets
News headline image
Better Mood Day ↗
May 20, 2021
The US Treasury plans to require IRS reporting on US cryptocurrency trades of $10,000 and up to prevent tax evasion. 
Via Talk Markets
News headline image
Why Biogen's June 7 Aducanumab PDUFA Date Is A High-Risk, High-Reward Catalyst ↗
May 19, 2021
As the day of reckoning for Biogen Inc.'s (NASDAQ: BIIB) controversial Alzheimer's product candidate aducanumab draws close, an analyst at Oppenheimer looked at the... 
Via Benzinga
News headline image
A Down Day ↗
May 12, 2021
The tech wreck continues because inflation will hurt the costly stock sector more than others. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs ↗
May 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
News headline image
Inflation Shock ↗
May 06, 2021
Markets are up because jobs data were much better than expected, below 500,000 for the first week since Covid-19 started last week. 
Via Talk Markets
News headline image
Tuesday Market Report ↗
April 27, 2021
Swiss ABB gained 0.8% more today after it reported on its Q1 today, confirming the pre-announced data from earlier in April. 
Via Talk Markets
News headline image
Robots ↗
April 19, 2021
Teva is suffering from fear of the legal risks of its opioid misselling which is overriding good news of its newer drugs. 
Via Talk Markets
News headline image
Electric Cancer Cure ↗
April 13, 2021
Most US stocks were down on fear of inflation and financial risks but then rose after lunch. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs ↗
April 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 22) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap